CEO UPDATE

Core Insights - Bright Green Corporation has experienced significant industry shifts in 2024, presenting growth opportunities for the company [1] EB-5 Investment Program - The company has confirmed its first three applications through its EB-5 investment program in partnership with Asia Capital Pioneers Group (ACPG), with more than a dozen additional investors beginning the investment process [2] - ACPG recently hosted a successful event with over 100 potential investors, indicating strong interest in the EB-5 program, with future events planned in Dubai, Singapore, and Malaysia [3] Commercialization of Controlled Substances - Bright Green is advancing its initiative to commercialize Schedule I and Schedule II controlled substances in the U.S., having submitted a DEA 2025 quota request for a total of 22 substances [4] - If approved, the company aims to handle 70% of all marijuana and THC production, 70% of mescaline production, and 50% of psilocybin and psilocyn production within the DEA's program [5] Facility and Production Plans - The company is collaborating with CEADL to upgrade its existing facility and prepare for production, with initial production expected by the end of Q1 2025 [6] Internal Developments - Bright Green has decided to establish its own in-house API and Plant Genetics Research and Medical team to leverage Smart Farming and AI technology, enhancing its agility in meeting the demand for controlled substances [9] Cannabis Reclassification - The DEA's initiative to reclassify cannabis as a Schedule III substance is viewed positively by the company, as it is expected to increase demand for cannabis as an active ingredient [10][11] - The company anticipates carrying 70% of the DEA's cannabis quota in the U.S. by 2025, positioning itself as the largest producer of DEA cannabis in the country [11] Strategic Vision - The company aims to pioneer the "Drugs Made in America" movement, creating a reliable domestic API supply chain and reducing dependence on foreign drug imports [13]